What Has Published Research Reported About Epithalon?

What is epithalon, and why are there several spellings?

Epithalon, also written epitalon or epithalone, is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly, abbreviated AEDG (sources 1, 5 and 7). A 2025 review by Araj and colleagues in the International Journal of Molecular Sciences described it as synthesized from the amino acid composition of epithalamin, a bovine pineal gland extract (source 7). The 2000 fruit fly paper used the spelling “epitalon,” the 2003 telomerase paper used “Epithalon,” and the 2020 paper in Molecules used “AEDG Peptide (Epitalon)” (sources 1, 4 and 5). This Steadfast Research Group profile covers only the peer-reviewed literature. Supplier and blog pages restate these findings, and sometimes enlarge them, so they were not used as sources.

The formula and masses above were calculated from the sequence for the free-acid form. They are not figures from any cited paper.

What did the 2000 fruit fly study report?

Khavinson, Izmaylov, Obukhova and Malinin, in a 2000 paper in Mechanisms of Ageing and Development, studied epitalon in the Canton-S wild-type strain of Drosophila melanogaster. The abstract stated that the substance was added to the culture medium only during development from egg to larva. The authors reported that adult lifespan rose by 11 to 16 percent and that the increase did not depend on concentration (source 1). The abstract as retrieved gave that single headline range, so separate mean and maximum lifespan values were not seen and are not reported here.

What did the two mouse lifespan studies report?

Anisimov, Khavinson, Mikhalski and Yashin reported the first mouse study in 2001 in Mechanisms of Ageing and Development. It used 50 female CBA mice and a saline control, and it also tested a synthetic thymic dipeptide; only the pineal tetrapeptide results are described here. The abstract reported an increase in mean survival of 5.3 percent, an increase in maximum survival of 10 months, slower aging of estrous function and a lower incidence of spontaneous tumors, mainly lung adenomas (source 2).

In 2003, Anisimov, Khavinson and colleagues published a second study in Biogerontology using female outbred Swiss-derived SHR mice, 54 per group, starting at 3 months of age and continuing until natural death. The abstract reported no change in food consumption, body weight or mean lifespan. It reported that maximum lifespan was 12.3 percent higher, that the last 10 percent of survivors lived 13.3 percent longer, that age-related loss of estrous function was slower and that bone marrow chromosome aberrations were 17.1 percent lower. Total spontaneous tumor incidence did not change, while the development of leukemia was inhibited (source 3).

The two mouse papers did not agree on every endpoint. Mean survival was 5.3 percent higher in the 2001 CBA study and unchanged in the 2003 SHR study, and tumor incidence was lower in one and unchanged in the other. The strain and the age at the start of exposure also differed, so the sources reviewed cannot say which factor explains the difference (sources 2 and 3).

What did the telomerase papers report?

Khavinson, Bondarev and Butyugov published “Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells” in the Bulletin of Experimental Biology and Medicine in 2003 (source 4). The title states the finding. The abstract itself was not retrieved, and secondary pages disagreed on the cell type and on pagination, so no figures from that paper are reported here.

The most recent telomere paper came from a different group. Al-Dulaimi and colleagues, at Brunel University London, published in Biogerontology in 2025 a study of epitalon in normal and breast cancer cell lines, measured by quantitative PCR and immunofluorescence. They reported that in normal cells hTERT mRNA expression, telomerase activity and average telomere length were higher. In the cancer cell lines they reported telomere lengthening through alternative lengthening of telomeres (ALT), without a significant rise in telomerase activity, and only a minor rise in ALT activity in normal cells. A correction published in November 2025 replaced figures in the paper, and its contents were not reviewed, so the corrected paper should be read before any value from it is cited (source 6).

What did the 2020 neural stem cell paper report?

Khavinson and colleagues, in a 2020 paper in Molecules, examined AEDG in human gingival mesenchymal stem cells. They reported higher protein levels of the neurogenic differentiation markers Nestin, GAP43, β-tubulin III and doublecortin, and mRNA levels of those four genes that were 1.6 to 1.8 times those of control cells. A molecular modelling analysis suggested that the peptide bound preferentially to histones H1/3 and H1/6 at sites that interact with DNA, and the authors proposed that this binding could be one route to the higher transcription (source 5). The paper’s own title calls the idea a “possible epigenetic mechanism.” The sources reviewed did not include a study that tested the binding directly.

How do the studies compare?

How independent is the epithalon evidence?

Khavinson is named as an author on five of the six primary papers in the table, so most of the findings come from one research network. The 2025 Brunel paper is the one primary study reviewed from outside it, and it carries a correction. No retraction or expression of concern was seen in the searches run for this profile, although journal notices were not checked one by one. The 2025 review by Araj and colleagues noted that most of the work on epithalon is preclinical (source 7). The sources reviewed contained no human trial, and the cell-culture telomere papers do not measure telomeres in a living animal.

How do laboratories confirm epithalon identity?

No analytical paper specific to epithalon was among the sources reviewed, so the workflow below is the general one used for any research peptide. A mass spectrum is compared with the calculated mass for the stated sequence, and an identity result is paired with a purity figure from a separate method such as HPLC. A Certificate of Analysis should state which structure and form it confirmed. The guides to reading a peptide COA, mass spectrometry verification and HPLC purity testing cover those checks.

What terms recur in the epithalon literature?

Epithalamin

A bovine pineal gland extract from whose amino acid composition epithalon was described as synthesized (source 7).

AEDG

The one-letter abbreviation for the sequence Ala-Glu-Asp-Gly (sources 1 and 7).

hTERT and telomerase activity

The catalytic subunit transcript and the enzyme activity that source 6 measured in normal and cancer cell lines.

ALT

Alternative lengthening of telomeres, the telomerase-independent route that source 6 reported for the cancer cell lines.

Maximum lifespan

A survival endpoint that sources 2 and 3 reported separately from mean lifespan; source 3 also reported the last 10 percent of survivors.

Canton-S

The wild-type Drosophila strain used in source 1.

What remains unresolved in the epithalon literature?

Several limits apply. The two mouse studies differed on mean survival and tumor incidence, and the fruit fly result was reported as a single range. The 2003 telomerase paper was read at title level only, and the 2025 paper was corrected after publication. The histone-binding idea came from modelling in one paper. Every source was read at abstract or search-summary level, and the amounts given to animals and many numerical results were left out because they could not be confirmed from the abstracts. A different short peptide framed in aging research is profiled in the GHK-Cu research profile, and the P021 profile applies the same provenance screen to another compound whose papers cluster in one research network.